The large, ongoing CIRCULATE-Japan trial is investigating the role of circulating tumor DNA (ctDNA)-based molecular residual disease testing in patients with resectable colorectal cancer after radical surgery. An interim analysis of GALAXY, a prospective, observational arm of CIRCULATE-Japan, establishes ctDNA as a prognostic and predictive biomarker.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yoshino, T. et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann. Oncol. 32, 1496–1510 (2021). This publication reports the current clinical practice guidelines for CRC.
O’Connor, E. S. et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 29, 3381–3388 (2011). This study demonstrates a lack of overall survival benefit from adjuvant chemotherapy for patients with stage II CRC.
Sobrero, A. F. et al. A new prognostic and predictive tool for shared decision making in stage III colon cancer. Eur. J. Cancer. 138, 182–188 (2020). This study highlights variability in treatment outcomes among patients with stage III CRC.
Taniguchi, H. et al. CIRCULATE-Japan: circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer. Cancer Sci. 1, 14926 (2021). This publication discusses the clinical trial protocol associated with CIRCULATE-Japan.
Kasi, P. M. et al. Impact of circulating tumor DNA-based detection of molecular residual 414 disease on the conduct and design of clinical trials for solid tumors. JCO Precis. Oncol. 6, e2100181 (2022). A review article that presents the clinical utility of ctDNA and its effect on clinical trial design.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
This is a summary of: Kotani, D. A. et al. Molecular residual disease and efficacy of adjuvant chemotherapy in patients with colorectal cancer. Nat. Med. https://doi.org/10.1038/s41591-022-02115-4 (2023).
Rights and permissions
About this article
Cite this article
Postoperative circulating tumor DNA could guide CRC adjuvant treatment. Nat Med 29, 39–40 (2023). https://doi.org/10.1038/s41591-022-02119-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41591-022-02119-0